دورية أكاديمية
Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
| العنوان: | Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. |
|---|---|
| المؤلفون: | Steenbeek MP; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., van Bommel MHD; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands. Electronic address: Majke.vanBommel@radboudumc.nl., Harmsen MG; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Hoogerbrugge N; Radboud University Medical Center, Department of Human Genetics, PO Box 9101, 6500, HB, Nijmegen, the Netherlands., van Doorn HC; Department of Gynecology, Erasmus MC Cancer Clinic, 's, Gravendijkwal 230, 3015, CE, Rotterdam, the Netherlands., Keurentjes JHM; Department of Gynecologic Oncology, University of Groningen, University Medical Centre Groningen, Hanzeplein 1, 9713, GZ, Groningen, the Netherlands., van Beurden M; Centre for Gynecological Oncology Amsterdam (CGOA), Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands., Zweemer RP; Department of Gynecological Oncology, UMC Utrecht Cancer Centre, Heidelberglaan 100, 3584, CX, Utrecht, the Netherlands., Gaarenstroom KN; Department of Obstetrics and Gynecology, Leiden University Medical Centre, Albinusdreef 2, 2333, ZA, Leiden, the Netherlands., Penders CGJ; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, GROW-School for Oncology and Developmental Biology, P. Debyelaan 25, 6229 HX Maastricht, the Netherlands., Brood-van Zanten MMA; Department of Obstetrics and Gynaecology, Amsterdam UMC, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands; Department of Obstetrics and Gynecology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands., Vos MC; Gynecologic Oncologic Centre South location Elisabeth-TweeSteden Hospital, Hilvarenbeekseweg 60, 5000, LC, Tilburg, the Netherlands., Piek JM; Gynecologic Oncologic Centre South location Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, the Netherlands., van Lonkhuijzen LRCW; Department of Obstetrics and Gynaecology, Amsterdam UMC, Meibergdreef 9, 1105, AZ, Amsterdam, the Netherlands., Apperloo MJA; Department of Obstetrics and Gynecology, Medical Centre Leeuwarden, Henri Dunantweg 2, 8934, AD, Leeuwarden, the Netherlands., Coppus SFPJ; Department of Obstetrics and Gynecology, Maxima Medical Centre, De Run 4600, 5504, DB, Veldhoven, the Netherlands., IntHout J; Radboud University Medical Center, Radboud Institute for Health Sciences, Department for Health Evidence, PO Box 9101, 6500, HB, Nijmegen, the Netherlands., de Hullu JA; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Obstetrics and Gynecology, Nijmegen, the Netherlands., Hermens RPMG; Radboud University Medical Center, Scientific Institute for Quality of Healthcare, PO Box 9101, 6500, HB, Nijmegen, the Netherlands. |
| المصدر: | Gynecologic oncology [Gynecol Oncol] 2021 Nov; Vol. 163 (2), pp. 371-377. Date of Electronic Publication: 2021 Aug 27. |
| نوع المنشور: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, Academic Press. |
| مواضيع طبية MeSH: | Decision Making* , Decision Support Techniques* , Genetic Predisposition to Disease*, Ovarian Neoplasms/*prevention & control , Prophylactic Surgical Procedures/*statistics & numerical data, Adult ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Feasibility Studies ; Female ; Health Knowledge, Attitudes, Practice ; Heterozygote ; Humans ; Middle Aged ; Mutation ; Ovarian Neoplasms/genetics ; Ovariectomy/psychology ; Ovariectomy/statistics & numerical data ; Patient Preference ; Prophylactic Surgical Procedures/psychology ; Prospective Studies ; Salpingectomy/psychology ; Salpingectomy/statistics & numerical data ; Salpingo-oophorectomy/psychology ; Salpingo-oophorectomy/statistics & numerical data |
| مستخلص: | Objective: Risk-reducing surgery is advised to BRCA1/2 pathogenic variant (PV) carriers around the age of 40 years to reduce ovarian cancer risk. In the TUBA-study, a multicenter preference study (NCT02321228), BRCA1/2-PV carriers are offered a choice: the standard strategy of risk-reducing salpingo-oophorectomy or the novel strategy of risk-reducing salpingectomy with delayed oophorectomy. We evaluated feasibility and effectiveness of a patient decision aid for this choice. Methods: Premenopausal BRCA1/2-PV carriers were counselled for risk-reducing surgical options in the TUBA-study; the first cohort was counselled without and the second cohort with decision aid. Evaluation was performed using digital questionnaires for participating women and their healthcare professionals. Outcome measures included actual choice, feasibility (usage and experiences) and effectiveness (knowledge, cancer worry, decisional conflict, decisional regret and self-estimated influence on decision). Results: 283 women were counselled without and 282 women with decision aid. The novel strategy was chosen less frequently in women without compared with women with decision aid (67% vs 78%, p = 0.004). The decision aid was graded with an 8 out of 10 by both women and professionals, and 78% of the women would recommend this decision aid to others. Users of the decision aid reported increased knowledge about the options and increased insight in personal values. Knowledge on cancer risk, decisional conflict, decisional regret and cancer worry were similar in both cohorts. Conclusions: The use of the patient decision aid for risk-reducing surgery is feasible, effective and highly appreciated among BRCA1/2-PV carriers facing the decision between salpingo-oophorectomy or salpingectomy with delayed oophorectomy. Competing Interests: Declaration of Competing Interest The authors declare that there is no conflict of interest. (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: BRCA; Decision aid; Ovarian cancer; Risk-reducing salpingo-oophorectomy; Salpingectomy |
| المشرفين على المادة: | 0 (BRCA1 Protein) 0 (BRCA1 protein, human) 0 (BRCA2 Protein) 0 (BRCA2 protein, human) |
| تواريخ الأحداث: | Date Created: 20210830 Date Completed: 20220106 Latest Revision: 20220106 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.ygyno.2021.08.019 |
| PMID: | 34456057 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1095-6859 |
|---|---|
| DOI: | 10.1016/j.ygyno.2021.08.019 |